Role of contrast enhanced ultrasound in the assessment of biliary duct disease

Zeno Spârchez, Pompilia Radu

3rd Medical Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Department of Ultrasound, Cluj Napoca, Romania

Abstract

The introduction of microbubble contrast agents (CA), which act as blood pool tracers, has overcome the limitations of conventional B-Mode, colour or power Doppler ultrasound, enabling the display of parenchymal microvasculature. Initially, the use of CA was accepted for hepatic lesions. In the following years, experts have expanded recommendations, as a result of the method’s efficiency in extrahepatic applications. In this article we review the methodology and the application of contrast-enhanced ultrasound (CEUS) in the evaluation of biliary pathology. This new imaging tool allows a non invasive differential diagnosis of biliary lesions and a clearer delineation of the tumoral process.

Keywords: bile duct tumors, ultrasound, contrast enhanced ultrasound

Introduction

Conventional ultrasound examination (US) has several advantages, such as real-time scanning, easy manipulation, cost-effectiveness, no radiation, high resolution, and repeatability. All these factors have turned this imaging tool into the first-line investigation in the assessment of biliary pathology. Some improvements in the image quality and the introduction of new techniques such as power Doppler, tissue harmonic imaging, 3D imaging and endoscopic ultrasound have increased the diagnostic capabilities of US in the biliary tree [1-3].

In the detection of intrahepatic or extrahepatic bile duct dilatation, ultrasound has up to 100% sensitivity for experienced examiners [3]. However, this imaging tool lacks the ability to depict microcirculation, an important disadvantage that may lead to failure to establish the nature and the clear delimitation of a biliary tumour.

The microbubble based US contrast agents (USCA) are completely intravascular agents; therefore, their use allows a clear depiction of macro- and micro-circulation of the target lesion, which may lead to an accurate diagnosis. Two important features of these CA should also be mentioned: the non-radioactive character and the use in patients with renal impairment [4]. Although numerous studies have shown promising results of CEUS since 2004, its use in the biliary system was mentioned in the “Guidelines and Good Clinical Practice Recommendation for CEUS” only in the 2011 update [5].

Dose of contrast agent, equipment and technique

Contrast agents: types and doses.

The USCA used in daily practice in Europe is SonoVue® (BR1; Bracco SpA, Milan, Italy). The dose depends on the objectives of the study. Therefore, a dose of 2.4 mL is necessary to characterize a biliary tumour, while in order to depict the biliary tree by intrabiliary administration, only a few drops of SonoVue are recommended [5].

Technique

Each patient needs to be fasted for at least 8 hours before examination. CEUS examination should be pre-
eced by a careful assessment of the target lesion with conventional B-mode US. After identification of the target lesion, the transducer is kept in a stable position, while the imaging mode is changed to CEUS, and the mechanical index (MI) settings are adjusted to provide sufficient tissue cancellation, with the maintenance of an adequate depth penetration. A stopwatch is started at the time of SonoVue administration.

For biliary ducts tumour (benign or malignant): SonoVue is administered via the antecubital vein, in a bolus fashion (within 1–2 s), followed by a flush of 10 mL of 0.9% normal saline by using a 20-gauge cannula. The entire CEUS process for the intrahepatic biliary system has to be performed with reference to the adjacent liver parenchyma, starting with arterial (8-30 s from the beginning of CA administration), portal (31-120 s), and finishing with the late (121-360 s) phase. The blood supply of the extrahepatic bile duct is entirely arterial. Therefore, the evaluation needs to be performed in the early phase (10-30 s after contrast injection), as well as in the late phase (31-180 s after contrast injection) [6].

In the late phase, for patients suspected of malignancy, a liver scanning is mandatory to exclude liver metastasis.

For intracavitary evaluation (biliary ducts): administration is performed through a drainage tube which is inserted into a biliary duct. No standard dosage of UCA has been established for intracavitary injection. The reported range is 0.1 mL–1 mL SonoVue® (most commonly just a few drops) diluted in 20 mL or more of 0.9% saline solution. This solution is drawn in a 20-mL injection syringe and slowly injected through the tube [5].

Intrahepatic bile ducts

Biliary cystadenoma

Biliary cystadenomas are relatively rare tumours, which tend to occur predominantly in women in their fifth decade. Although it is histologically benign, this tumour has indication for resection, due to its tendency to transform into a cystadenocarcinoma [6].

The typical appearance on US examination is well-defined typically multilocular cystic lesion with a thick wall containing multiple septations or papillary projections.

The CEUS examination in arterial phase may reveal highly echogenic septations, enhancing wall nodules or papillary projections. The enhancement washes out progressively and becomes iso- or hypo-enhancement during the portal and late phases (fig1) [6]. CEUS examination is helpful in evaluating nodule vascularity and facilitates the final diagnosis. Although, it is important to admit that CEUS is not superior to B-scan for the differential diagnosis of cystadenomas and cystadenocarcinomas.

Though it is a rare complication, intracystic bleeding may occur [7]. Due to the secreted mucin, that can mimic intracystic bleeding, the diagnosis of a real intracystic bleeding is very difficult to perform using US alone. According to Naganuma H et al [7] findings, intracystic bleeding can be diagnosed through the use of CEUS. Unlike a regular examination, the evaluation of the cyst in this case should be performed after 5 minutes from the moment of the intravenous injection of the contrast agent.

Intrahepatic cholangiocarcinoma

Intrahepatic cholangiocarcinoma (ICC) originates in the small bile ducts. It has a poor prognostic, as a result of the patient’s late presentation and lack of effective non-surgical therapeutic modalities [8]. Although ICC is a relatively rare tumour, its worldwide incidence rate has increased steadily in recent years. Since it may develop into cirrhotic livers, it is essential to differentiate between HCC and ICC.

The US features of ICC are nonspecific. It can appear as a solitary mass with satellite nodules or as diffusely abnormal liver echotexture. The bile ducts peripheral to the tumour mass are usually dilated. Tumour mass may be hypoechoic, hyperechoic, or it may display mixed echogenicity, with irregular borders. Colour Doppler US typically shows a poor colour signal within the tumour.

Imaging findings of ICC showed on CEUS in the arterial phase may be: a) a peripheral irregular rim-like hyperenhancement; b) heterogeneous hypoenhancement and c) heterogeneous hyperenhancement. However, all
Cholangiocarcinomas show hypoenhancement in the late vascular phase (Fig 2) [6,8,9]. The enhancement pattern of ICC seemed to change during the course of the tumour’s growth. According to Xu HX et al, most ICCs that are less than 3 cm enhance homogeneously (Fig 3), while those over 3 cm enhance heterogeneously or show a peripherally enhancing rim [6]. Another study showed that the hyperenhancing areas on CEUS exam correspond to abundant carcinoma cell areas. Thus, the authors concluded that CEUS findings of ICC are correlated to the degree of carcinoma’s cell proliferation [8]. In a study that compared the contrast enhanced – CT (CECT) exam with CEUS, the accuracy diagnosis was 80 % for CEUS and 67.5 % for CECT. Therefore, CEUS seems to be a new modality for the characterization of ICC [10].

Hepatocellular carcinoma with bile ducts invasion

The portal vein invasion is recognized as a prognostic factor in patients with hepatocellular carcinoma (HCC). Even if it is a rare complication, the bile duct invasion should be considered. The biliary ducts may be affected by direct duct invasion of HCC or by embolisation of HCC in the bile duct, without an obvious parenchymal lesion (icteric-type HCC). Two mechanisms for “icteric type HCC” growth have been proposed: migration of tumour cells into the bile duct and the development of HCC from an ectopic liver parenchyma. The main differential diagnosis of these entities has to be performed with intrahepatic cholangiocarcinoma (including its polypoid variant).

For parenchymal HCC with invasion of biliary ducts, CEUS examination reveals a homogeneous or heterogeneous hyperenhancement during the arterial phase, as well as washout during the portal or late phase [9].

For the “icteric type HCC“, US examination reveals an iso /low-echoic intraluminal polypoid lesion with irregular or smooth surface, depending on the presence of necrosis. CEUS examination shows the characteristic early enhancement pattern of HCC. Because intraductal tumoral thrombi are formed of tumour cells with necrotic materials or a mixture of tumour cells and hematoma, CEUS can demonstrate irregular or sludge-like lesions in the ducts with no enhancement (Fig 4).

Hilar cholangiocarcinoma

This biliary tumour known also as Klatskin’s tumour originates at the bifurcation of the hepatic ducts. The lack of symptoms and the difficulties of visualization in an early stage lead to a late diagnosis, thus only less than a half of patients can benefit from surgical resection. In order to establish whether a patient is a candidate for curative resection, an accurate imaging test is mandatory.

The US features of hilar cholangiocarcinoma are non-specific. The first clue and sometimes the only finding is the dilatation of the intrahepatic bile ducts. On conventional US, this tumour may be infiltrative, exophytic or polypoid. Due to the isoechoic appearance, respectively infiltrative pattern of growth, the detection of the tumour...
Role of contrast enhanced ultrasound in the assessment of biliary duct disease

With its delineating border is sometimes extremely difficult, especially for an inexperienced examiner [6,11,12].

On CEUS examination during the arterial phase, the tumour can appear either with peripheral irregular rim-like hyperenhancement, or as a diffuse heterogeneous hyperenhancement [12]. As enhancement the tumours are hyper-enhanced, isoenhanced and hypo-enhanced in 43.8%, 43.8%, and 12.4% of cases [6]. In the late phase, the tumour appears hypoenhanced, in comparison with adjacent enhanced liver parenchyma, thus the tumour border is well delineated and the infiltration extent is well depicted (fig 5). The enhancement features are related to the histological characteristics of the tumour and CA (blood pool agent). Pathologically, 70% of tumours are sclerosing adenocarcinomas, with mass of fibrous tissue hyperplasia around the gland cavity [11].

According to Xu HX et al, through the use of CEUS, the conspicuousity of the tumour has been defined as definitely distinct in 93.8 % cases, which was a significantly higher rate than in the case of the CECT examination (78.1%). Also, through the use of this method, the diagnosis accuracy for portal vein or hepatic duct invasion has increased up to 90% [11].

Extrahepatic biliary ducts

Villous adenoma

Villous adenomas are benign epithelial lesions with malignant potential, rarely encountered in the biliary tree. It is difficult to differentiate villous adenoma in the extrahepatic bile duct from biliary sludge, since they have similar echogenicity on US examination.

On CEUS examination in the arterial phase, the mass shows homogeneous enhancement. In the late phase, the enhancement decreases gradually, so that the mass becomes hypo-enhanced towards the end of the late phase [6].

Ampullary carcinoma

Ampullary tumours are relatively uncommon, representing only 1.5 per cent of gastrointestinal tract tumours. Due to the localization of ampulla, the role of US in the diagnosis of ampullary carcinoma is low. So, in general, on US examination, indirect signs such as bile duct or pancreatic duct dilatation are visualized.

On CEUS examination in the arterial phase, the tumour is iso-enhanced and becomes hypo-enhanced in the late phase (fig 6). According to Kiura et al, the type of enhancement of ampullary tumour may offer supplementary information regarding the growth pattern [13]. The enhancement in arterial phase may differentiate this tumour from other lesions arising at this level, such as hypervascular GISTs or neuroendocrine tumours.

Intrabiliary metastasis

Intrabiliary metastases are rare, and their imaging features make them easy to confuse with primary biliary tumours, especially with cholangiocarcinoma. The primary tumours known as causing metastatic biliary obstruction include colonic cancer, malignant melanoma, lymphoma, gallbladder, ovary, duodenum, oesophagus, liver, cervix, uterus, muscle, prostate, bone, and brain. Most often, the intrabiliary metastasis originates in colonic carcinoma.

On US examination, these tumours often appear as solid masses associated with dilated peripheral ducts. For a right diagnosis, two steps are essential: to determine the nature of the intrabiliary lesion (benign or malignant) and to establish the type of malignant tumour (cholangiocarcinoma, HCC or metastasis).

In a study conducted by Lee YJ, there is a difference of enhancement between intraductal metastasis and cholangiocarcinoma. Thus, intraductal metastasis tends to exhibit hypervascularity in the arterial phase, whereas intraductal cholangiocarcinoma has a tendency towards isoattenuation (fig 7) [14].
Nontumoral intrabiliary masses like pus, clots, parazites, sludge or nonshadowing stones can be differentiated with high accuracy from tumors by means of CEUS (fig 8).

Non tumoral biliary pathology

Portal hypertensive biliopathy (PHB)

Portal hypertensive biliopathy is defined as an abnormality of the walls of the biliary tree secondary to portal hypertension. It is usually diagnosed incidentally; however, a small percentage of patients develop symptomatic bile duct obstruction. The drainage veins of the common bile duct form a pericholedochal and paracholedochoal venous plexus. Hypertrophy of both collateral plexuses produces mural irregularities, and sacular dilatation, which can progress to stenosis. The main differential diagnosis is with cholangiocarcinoma.

US examination reveals a thickened wall of the common bile duct. In 35% of patients with PHB, gallbladder varices are also described [15].

On CEUS examination after SonoVue injection, the paracholedochoal veins become enhanced, and appear as beads. After several seconds, the pericholedochoal veins become linearly enhanced. Thereafter, the whole bile ducts gradually become enhanced (fig 9). Using this imaging method, a clear differentiation between the dilatation of paracholedochoal veins and pericholedochoal venous plexuses can be distinguished [16].

Periductal inflammation

Inflammation of the bile ducts may occur in acquired immunodeficiency syndrome (AIDS) patients, owing to an opportunistic infection or in patients with intrahepatic cholelithiasis.
On US examination, a wall thickening of the bile duct and hypoechoigenicity around the intrahepatic bile duct may appear.

CEUS examination shows hyper-enhancement during the arterial phase and hypo-enhancement during the late phase [6].

Contrast agent injection into biliary ducts

**Bile duct drainage**

With accuracy between 96% and 100% in detecting biliary obstruction, X-ray percutaneous transhepatic cholangiography (PTC) was considered once the standard method to evaluate the level of obstruction [17,18]. In spite of this, it has several important disadvantages: it is radioactive and inappropriate for patients that are sensitive to iodine. Another drawback is the fact that PTC had an accuracy of only 63% in determining the cause of obstruction [19]. According to the latest reports, percutaneous ultrasound cholangiography (PUSC) provides visualization of the bile ducts as small as fifth-order branches [20]. Regarding the accuracy of PUSC in determining the level and the cause of obstruction, Luyao Z et al concluded that this new method is comparable to PTC and may be used as an alternative method to X-ray PTC (fig 10) [19].

Percutaneous transhepatic biliary drainage (PTBD) is an alternative method for the palliative treatment of a malignant biliary obstruction. In order to ensure the effectiveness of the drainage, it is critical to identify the tip of the drainage catheter. Drainage tubes can be detected by US, but they can hardly be seen in their full length and the tip position is often difficult to locate. In 2012 Xu EJ et al, demonstrated that PUSC improved the visualization of the drainage catheters and location of their tips. Also, the diagnostic accuracy of PUSC for biliary obstruction level was as high as 100% [21].

**Biliary leakage**

Until 2010, PTC was the preferred examination for diagnosis of biliary leakage due to its high sensitivity and anatomic resolution. However, due to the above mentioned disadvantages other possible applications of PUSC have emerged. These evaluate possible complications after T tube removal (biliary leakage) and liver transplantation (anastomotic). For the diagnosis of leakage or stenosis, X-ray PTC has proven to be more accurate than PUSC. The main cause was the presence of gas inside the bowels. By contrast, the image quality of the intrahepatic bile ducts regarding the visualization of ductal branches was comparable to X-ray PTC [22]. In 2010, Mao R et al, demonstrated the utility of PUSC in diagnosis of biliary leakage after T tube removal [23].

**Conclusions**

CEUS is a complementary method that can be utilized for supplementary evaluation of US findings. The summarized indications for evaluating biliary ducts with CEUS are: (1) to perform a differential diagnosis between intrahepatic cholangiocarcinoma and other tumors (hepatocellular carcinoma or liver metastasis), (2) to characterize the biliary cystadenoma and diagnose complications; (4) to depict the borders of Klatskin’s tumor with greater clarity; (5) to make a distinction between polyloid cholangiocarcinoma and intrabiliary metastasis; (6) to make a distinction between cholangiocarcinoma and benign ductal pathology (periductal inflammation or portal biliopathy); (7) to differentiate common bile duct cancers from nonmalignant intrabiliary lesions (pus, blood, sludge); (8) to identify the tip location of the drainage catheter and the presence of biliary leakage.

This imaging method is particularly useful for those patients for whom the use of contrast agents in CT or MR imaging is contraindicated (renal impairment and allergy to CA). It is also important to highlight the fact that limitations encountered in US examination are not totally eliminated by CEUS examination.

**Conflict of interest:** none

**References**